Early treatment results of locally advanced (stage III) breast cancer Lokal ileri evre (evre III) meme kanserlerinde erken tedavi sonuclarimiz


KAPLAN B., Karahacioglu E., ALTINBAŞ M., Bora H., Soyuer S., YILDIZ O. G., ...Daha Fazla

Erciyes Tip Dergisi, cilt.21, sa.1, ss.47-51, 1999 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 1
  • Basım Tarihi: 1999
  • Dergi Adı: Erciyes Tip Dergisi
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.47-51
  • Anahtar Kelimeler: Breast neoplasms, Radiotherapy, Tamoxifen
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Purpose: In this retrospective study, 46 patients with locally advanced, non metastatic, non inflammatory breast cancer who were treated with postoperative radiotherapy (RT) chemotherapy (CT) ± tamoxiphene (Tmx.) were assessed in terms of overall survival and disease free survival rates. Patients and methods: The patients involved in the study were treated at Erciyes University Gevher Nesibe Hospital between 1992-1995 The median age of patients is 49 (28-74) years and the median follow-up is 26 (6-47) months. In general, the patients were treated primarily by surgery, CT and/or RT was administered after surgery (S). Systemic treatment consisted of a combination of CMF, FEC or FAC in four-six cycles. Thirteen patients were not given CT. Fifty gray RT was given to regional lymph nodes and chest wall. Results: Since the follow-up was 26 months according to Kaplan-Meier's four years' projected survival; the overall four-year survival rate was 21.86%, and four- year disease-free survival was 13.67%. In the CT and RT ± Trax. group, (33 patients), the overall four-year survival rate was 41.28 % while in 13 patients who were not green CT, this was 28 76 % (p = 0 48). In 33 patients treated with S, RT and CT ± Tmx., the four-year disease-free survival rate was 17.90%; in patients who were not given CT, this was 16.76 % (p= 0.49). Conclusion: Multimodal treatment which consisted of S, RT and CT ± Tmx was more effective in locally advanced breast cancer.